We are live on ! Find out more
AKBA icon

Akebia Therapeutics

82 hedge funds and large institutions have $146M invested in Akebia Therapeutics in 2015 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 16 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 16

82% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 11

12% more funds holding

Funds holding: 7382 (+9)

7% more capital invested

Capital invested by funds: $136M → $146M (+$9.98M)

14% less call options, than puts

Call options by funds: $1.23M | Put options by funds: $1.43M

Holders
82
Holders Change
+9
Holders Change %
+12.33%
% of All Funds
2.29%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
32
Reduced
16
Closed
11
Calls
$1.23M
Puts
$1.43M
Net Calls
-$206K
Net Calls Change
-$310K
Name Holding Trade Value Shares
Change
Change in
Stake
JIC
26
Johnson Investment Counsel
Ohio
$946K +$207K +22,613 +30%
BCM
27
Bridgeway Capital Management
Texas
$934K
BIM
28
BlackRock Investment Management
Delaware
$914K +$35.6K +3,877 +4%
FWIA
29
Fort Washington Investment Advisors
Ohio
$908K
Connor, Clark & Lunn Investment Management (CC&L)
30
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$864K +$482K +52,525 +142%
TCIM
31
TIAA CREF Investment Management
New York
$813K -$48.2K -5,257 -6%
TI
32
Trexquant Investment
Connecticut
$700K +$665K +72,500 New
CCI
33
Columbus Circle Investors
$627K +$596K +64,953 New
Citadel Advisors
34
Citadel Advisors
Florida
$616K +$508K +55,340 +654%
HCM
35
Highbridge Capital Management
New York
$609K +$578K +63,016 New
Charles Schwab
36
Charles Schwab
California
$601K +$161K +17,507 +39%
TAM
37
Tocqueville Asset Management
New York
$580K +$551K +60,000 New
RFC
38
Russell Frank Company
Washington
$531K +$504K +54,918 New
NCCM
39
Nine Chapters Capital Management
New Jersey
$492K -$95.4K -10,400 -17%
ERSOT
40
Employees Retirement System of Texas
Texas
$483K
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$428K -$1.83K -200 -0.4%
EA
42
Emerald Advisers
Pennsylvania
$415K
Parallax Volatility Advisers
43
Parallax Volatility Advisers
California
$412K +$392K +42,700 New
TA
44
Teachers Advisors
New York
$341K -$20.9K -2,273 -6%
GGHC
45
Gilder Gagnon Howe & Co
New York
$326K +$310K +33,733 New
SIP
46
Stoneridge Investment Partners
Pennsylvania
$323K -$2.75K -300 -0.9%
Simplex Trading
47
Simplex Trading
Illinois
$320K +$304K +33,148 New
UBS Group
48
UBS Group
Switzerland
$319K -$305K -33,244 -50%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$307K +$17K +1,848 +6%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$305K +$22.2K +2,418 +8%

AKBA Hedge Fund Activity: Q3 2015 in Review

82 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2015, worth a combined $146M — up 7.4% from $136M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new AKBA positions and 11 closed out — a net gain of 9 holders — while 32 added to existing stakes and 16 trimmed.

The largest buyer was Eagle Asset Management, adding an estimated $7.65M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $8.52M sold.

  • 82 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2015, up from 73 in Q2 2015.
  • Funds reported $146M of Akebia Therapeutics stock for Q3 2015, up 7.4% quarter-over-quarter.
  • 20 funds opened new Akebia Therapeutics positions in Q3 2015 and 11 closed out, a net change of +9 holders.
  • The largest Akebia Therapeutics buyer in Q3 2015 was Eagle Asset Management, an estimated $7.65M added.
  • The largest Akebia Therapeutics seller in Q3 2015 was Balyasny Asset Management, an estimated $8.52M sold.

Based on aggregated 13F filings for Q3 2015.